Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

677 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma.
Amioka K, Kawaoka T, Kinami T, Yamasaki S, Kosaka M, Johira Y, Yano S, Naruto K, Ando Y, Fujii Y, Uchikawa S, Ono A, Yamauchi M, Imamura M, Kosaka Y, Ohya K, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Morio K, Moriya T, Naeshiro N, Nonaka M, Aisaka Y, Azakami T, Hiramatsu A, Aikata H, Oka S. Amioka K, et al. Among authors: masaki k. Cancers (Basel). 2022 Oct 16;14(20):5066. doi: 10.3390/cancers14205066. Cancers (Basel). 2022. PMID: 36291850 Free PMC article.
Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Ando Y, Kawaoka T, Suehiro Y, Yamaoka K, Kosaka Y, Uchikawa S, Kodama K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Fukuhara T, Mori N, Takaki S, Tsuji K, Nonaka M, Hyogo H, Aisaka Y, Masaki K, Honda Y, Moriya T, Naeshiro N, Azakami T, Takahashi S, Imamura M, Chayama K, Aikata H. Ando Y, et al. Among authors: masaki k. Oncology. 2020;98(11):787-797. doi: 10.1159/000509387. Epub 2020 Sep 3. Oncology. 2020. PMID: 32882687
Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy.
Amioka K, Kawaoka T, Ogawa Y, Kikukawa C, Naruto K, Yoshikawa Y, Ando Y, Kosaka Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M, Fukuhara T, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Chayama K, Aikata H. Amioka K, et al. Among authors: masaki k. Oncology. 2021;99(5):327-335. doi: 10.1159/000514315. Epub 2021 Mar 5. Oncology. 2021. PMID: 33677453
Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y, Kawaoka T, Amioka K, Naruto K, Ogawa Y, Yoshikawa Y, Kikukawa C, Kosaka Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Fukuhara T, Mori N, Takaki S, Tsuji K, Nonaka M, Hyogo H, Aisaka Y, Masaki K, Honda Y, Moriya T, Naeshiro N, Takahashi S, Imamura M, Chayama K, Aikata H. Ando Y, et al. Among authors: masaki k. Oncology. 2021;99(8):507-517. doi: 10.1159/000515865. Epub 2021 May 4. Oncology. 2021. PMID: 33946070
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.
Amioka K, Kawaoka T, Kosaka M, Johira Y, Shirane Y, Miura R, Murakami S, Yano S, Naruto K, Ando Y, Kosaka Y, Fujii Y, Kodama K, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Moriya T, Naeshiro N, Nonaka M, Hyogo H, Aisaka Y, Azakami T, Hiramatsu A, Aikata H. Amioka K, et al. Among authors: masaki k. Cancers (Basel). 2022 Jan 10;14(2):320. doi: 10.3390/cancers14020320. Cancers (Basel). 2022. PMID: 35053484 Free PMC article.
Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.
Honda Y, Kimura T, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Naeshiro N, Ono A, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Ishikawa M, Kakizawa H, Kenjo M, Takahashi S, Awai K, Nagata Y, Chayama K. Honda Y, et al. Among authors: masaki k. J Gastroenterol Hepatol. 2013 Mar;28(3):530-6. doi: 10.1111/jgh.12087. J Gastroenterol Hepatol. 2013. PMID: 23216217
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Kodama K, Kawaoka T, Aikata H, Uchikawa S, Nishida Y, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Masaki K, Honda Y, Mori N, Takaki S, Tsuji K, Kohno H, Kohno H, Moriya T, Nonaka M, Hyogo H, Aisaka Y, Kimura T, Nagata Y, Chayama K. Kodama K, et al. Among authors: masaki k. Oncology. 2018;94(4):215-222. doi: 10.1159/000486483. Epub 2018 Feb 9. Oncology. 2018. PMID: 29428943
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
Kodama K, Kawaoka T, Aikata H, Uchikawa S, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Masaki K, Honda Y, Mori N, Takaki S, Tsuji K, Kohno H, Kohno H, Moriya T, Nonaka M, Hyogo H, Aisaka Y, Chayama K. Kodama K, et al. Among authors: masaki k. J Gastroenterol Hepatol. 2018 Oct;33(10):1780-1786. doi: 10.1111/jgh.14152. Epub 2018 May 10. J Gastroenterol Hepatol. 2018. PMID: 29645345
Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis.
Ohya K, Imamura M, Teraoka Y, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Mori N, Takaki S, Tsuji K, Aisaka Y, Ishitobi T, Katamura Y, Kodama H, Nabeshima Y, Masaki K, Honda Y, Moriya T, Kohno H, Kohno H, Chayama K. Ohya K, et al. Among authors: masaki k. Hepatol Res. 2020 Nov;50(11):1234-1243. doi: 10.1111/hepr.13555. Epub 2020 Sep 11. Hepatol Res. 2020. PMID: 32914512
Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
Naruto K, Kawaoka T, Amioka K, Ogawa Y, Chihiro K, Yoshikawa Y, Ando Y, Suehiro Y, Kosaka Y, Uchikawa S, Kodama K, Morio K, Fujino H, Murakami E, Nakahara T, Yamauchi M, Tsuge M, Hiramatsu A, Fukuhara T, Takaki S, Mori N, Tsuji K, Nonaka M, Hyogo H, Aisaka Y, Masaki K, Honda Y, Kohno H, Kohno H, Moriya T, Naeshiro N, Azakami T, Imamura M, Chayama K, Aikata H. Naruto K, et al. Among authors: masaki k. Oncology. 2021;99(8):491-498. doi: 10.1159/000515280. Epub 2021 May 17. Oncology. 2021. PMID: 34000725
677 results